Hepatitis C News

BOSTON — According to an abstract at The Liver Meeting, patients of Hispanic ethnicity who had elevated liver enzymes at baseline remained at increased risk for hepatocellular carcinoma, despite spontaneously clearing hepatitis C virus.

As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment.

BOSTON — Use of directly observed therapy was successful even at extended intervals when treating hepatitis C virus infection among people who inject drugs, according to research presented at The Liver Meeting.

BOSTON — A regimen of sofosbuvir/velpatasvir with ribavirin was effective among patients with refractory chronic hepatitis C virus with liver cirrhosis and chronic kidney disease, according to data presented at The Liver Meeting.

BOSTON — A virtual treatment program that coordinates care with local providers improved therapy for children and adolescents with hepatitis C virus in the United Kingdom, according to a presentation at The Liver Meeting.

BOSTON — Implementation of universal hepatitis C virus screening at cancer centers and corresponding care may positively affect HCV elimination targets and improve public health outcomes, according to a presentation at The Liver Meeting.

BOSTON — There is a reduction in syringe sharing when methadone providers are spread out near areas with the greatest density of people who inject drugs, according to research presented at The Liver Meeting.

BOSTON — In this video, Norah Terrault, MD, MPH, FAASLD, discusses data from The Liver Meeting on treatment of hepatitis C virus infection among individuals with hepatocellular carcinoma.

Asian patients with hepatocellular carcinoma had the lowest waitlist dropout rates and highest 5-year survival after liver transplantation before and after the policy change, while Black or African American patients had the worst outcomes.

BOSTON — In this video, Norah Terrault, MD, MPH, FAASLD, spoke with Healio about a presentation from The Liver Meeting on “The Toronto Protocol,” an ultra-short course of glecaprevir/pibrentasvir with ezetimibe.